Navigation Links
Women at Greater Risk for Depression and Anxiety
Date:5/11/2009

Week, more than 1,000 events will take place across the country. For more information and to find an event in your community, visit www.womenshealth.gov/whw.

The Office on Women's Health (OWH) was established in 1991. OWH coordinates the efforts of all the U.S. Department of Health and Human Services' agencies and offices involved in women's health. The office works to improve the health and well-being of women and girls in the United States through its programs, by educating health professionals and motivating behavior change in consumers through the dissemination of health information.


'/>"/>
SOURCE The Office on Women's Health
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Work-Family Conflict Dogs Air Force Women After Deployment
3. Work-Family Conflict Dogs Air Force Women After Deployment
4. Antioxidant Supplements May Raise Womens Skin Cancer Risk
5. Early Weight Loss in Women Linked to Dementia
6. For Health Info, Women Often Turn to the Web
7. Smoking increases risks for head and neck cancers for men and women
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Passive smoking increases sleep disturbance among pregnant women
10. Trial to Test Gene Therapy for Angina in Women
11. Exercise and yoga improves quality of life in women with early-stage breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista ... 5, 2015, from 11 a.m. to 3 p.m. near Albertsons in the Foothill Center, ... to meet Dr. Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more ...
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric Disease ... with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author Dr ... been largely untreatable - with mostly palliative treatments only - and now we ...
(Date:8/31/2015)... ... 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been ... Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. ... in both sports in his senior year. He was inducted into the National Honor ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare meet the ... costs? , In a commentary for The American Journal of Managed Care ... “clinical efficacy,” which would bind parties together in agreements to intervene at the ...
(Date:8/31/2015)... ... August 31, 2015 , ... The dental implant and prosthetic market in ... of Implant Dentistry. (See Press Room ) More than 30 million Americans are ... With the increasing demand for dental implants, the National Association of Dental Laboratories (NADL) ...
Breaking Medicine News(10 mins):Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4
... Scientists have known which genes are linked ... University Baptist Medical Center have organized this information ... in studying the genetics of inflammatory diseases. , ... the researchers were able to systematically map out ...
... Limited,announced today that it will report efficacy data ... once-daily experimental cancer therapy CHR-2797 at the,forthcoming American ... oral aminopeptidase inhibitor currently in clinical development. The,company ... preclinical studies.,Details of the presentations are as follows:, ...
... Specifically for Resource-Limited ... Global Procurement Consortium, UPPSALA, Sweden, November 30 ... an agreement with the Clinton,Foundation HIV/AIDS Initiative (CHAI). Under ... to members of CHAI,s,Procurement Consortium at a discounted price. ...
... Pharmaceuticals is,pleased to announce that it received US ... strengths of 5mg, 10mg, 25mg and 50,mg, effective ... equivalent alternative to Urecholine(R) (a trademark of,Barr Laboratories)., ... Amneal, who is,one of the very first companies ...
... today,announced that the U.S. Drug Enforcement Administration (DEA) ... from,its Auburn, Wash. distribution center effective Dec. 3., ... the Washington facility,and only controlled substance shipments from ... of service to its customers., In an ...
... Smart Solutions to Keep Program,Accessible and Affordable, PHILADELPHIA, ... hosted a panel discussion with local voters to,address the ... the program after scheduled pay cuts go into effect ... the program to find a doctor. But with,Medicare enrollees ...
Cached Medicine News:Health News:Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 2Health News:Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring 3Health News:Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility 2Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: